NCT03119636

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Chinese Academy of Sciences · Other Government
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.

Detailed description

This study is a Phase I/II, open-label, non randomized clinical trial. The study will enroll 50 patients for cell injection, administering a single dose of neural precursor cells by stereotaxic intra-striatal injection.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
BIOLOGICAL	NPC transplantation	The cells are stereotactically implanted in the striatum.
DRUG	Levodopa	Levodopa is used depending on the patient's condition

Timeline

• Start date: 2017-05-01
• Primary completion: 2018-11-01
• Completion: 2020-12-01
• First posted: 2017-04-18
• Last updated: 2017-04-18

Locations

1 site across 1 country: China